Breast tissue–based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer

Eissa, Sanaa; Matboli, Marwa; Shehata, Hanan H.

doi:10.1016/j.trsl.2014.10.001

Cited by 32 publications

(20 citation statements)

References 30 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to using increases in specific isomiR as a biomarker, we also found that canonical miRNA, miR‐23a‐3p in our study, is expressed abundantly in BC and also has biomarker potential. Upregulated miR‐23a‐3p has been observed in BC, and plays a role in cancer progression through the MAPK pathway 50,51 . Although the mechanism by which individual isomiRs work in the gene regulation network remains poorly understood, our results suggest the importance of comprehensive analysis of miRNA expression, including isomiRs, as a way to provide more accurate biological information than analysis of canonical miRNAs alone.…”

Section: Discussionmentioning

confidence: 80%

Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles

et al. 2020

View full text Add to dashboard Cite

Emerging evidence indicates that small RNAs, including microRNAs (miRNAs) and their isoforms (isomiRs), and transfer RNA fragments (tRFs), are differently expressed in breast cancer (BC) and can be detected in blood circulation. Circulating small RNAs and small RNAs in extracellular vesicles (EVs) have emerged as ideal markers in small RNA‐based applications for cancer detection. In this study, we first undertook small RNA sequencing to assess the expression of circulating small RNAs in the serum of BC patients and cancer‐free individuals (controls). Expression of 3 small RNAs, namely isomiR of miR‐21‐5p (3′ addition C), miR‐23a‐3p and tRF‐Lys (TTT), was significantly higher in BC samples and was validated by small RNA sequencing in an independent cohort. Our constructed model using 3 small RNAs showed high diagnostic accuracy with an area under the receiver operating characteristic curve of 0.92 and discriminated early‐stage BCs at stage 0 from control. To test the possibility that these small RNAs are released from cancer cells, we next examined EVs from the serum of BC patients and controls. Two of the 3 candidate small RNAs were identified, and shown to be abundant in EVs of BC patients. Interestingly, these 2 small RNAs are also more abundantly detected in culture media of breast cancer cell lines (MCF‐7 and MDA‐MB‐231). The same tendency in selective elevation seen in total serum, serum EV, and EV derived from cell culture media could indicate the efficiency of this model using total serum of patients. These findings indicate that small RNAs serve as significant biomarkers for BC detection.

show abstract

Section: Discussionmentioning

confidence: 80%

Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In embryonic stem cells, the expression of miR‐23a was also elevated in response to BMP4, and miR‐23a in turn targeted SMAD5 thus creating a negative feedback loop for BMP signaling (Musto et al, ). Upregulation of miR‐23a expression has been reported in breast cancer, particularly in lymph node positive metastatic breast cancers (Li et al, ; Eissa et al, ). In turn, both up‐ and downregulation of miR‐23b expression has been linked with metastatic breast cancer (Jin et al, ; Pellegrino et al, ; Pincini et al, ; Ell et al, ).…”

Section: Discussionmentioning

confidence: 99%

Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion

Alarmo

Havunen

Häyrynen

et al. 2015

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Bone morphogenetic protein 4 (BMP4) is a remarkably powerful inhibitor of breast cancer cell proliferation, but it is also able to induce breast cancer cell migration in certain cellular contexts. Previous data demonstrate that BMP4 controls the transcription of a variety of protein-coding genes, but not much is known about microRNAs (miRNA) regulated by BMP4. To address this question, miRNA expression profiles following BMP4 treatment were determined in one mammary epithelial and seven breast cancer cell lines using microarrays. While the analysis revealed an extensive variation in differentially expressed miRNA across cell lines, four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment. Inhibition of their expression demonstrated an increase in BT-474 cell number, indicating that they possess tumor suppressive properties. However, with the exception of miR-106b-5p, these effects were independent of BMP4 treatment. Scratch assay with miR-16-5p and miR-106b-5p inhibitors on BMP4-treated MDA-MB-231 cells resulted in enhanced cell migration, suggesting that these miRNAs are engaged in BMP4-induced motility. Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes.

show abstract

“…FOXM1 is overexpressed in many cancers, including breast cancer, and its ectopic expression promotes cell invasiveness (Bergamaschi et al 2014). Repression of FOXM1 was associated with increased miR-211 (Song and Zhao 2015) and miR-23a (Eissa, et al 2015), and repressed breast cancer cell growth, migration and invasion in animal models.…”

Section: Mirna Regulation Of Erα Protein Interactors In Breast Cancermentioning

confidence: 99%

Roles for miRNAs in endocrine resistance in breast cancer

Muluhngwi¹,

Klinge²

2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

Therapies targeting estrogen receptor α (ERα) including selective estrogen receptor modulators (SERMs), e.g., tamoxifen; selective estrogen receptor downregulators (SERDs), i.e., fulvestrant (ICI 182,780); and aromatase inhibitors (AI), e.g., letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ERα. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The role of miRNAs in the progression of endocrine-resistant breast cancer is of keen interest in developing biomarkers and therapies to counter metastatic disease. This review focuses on miRNAs implicated as disruptors of antiestrogen therapies, their bona fide gene targets, and associated pathways promoting endocrine resistance.

show abstract

Breast tissue–based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer

Cited by 32 publications

References 30 publications

Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles

Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles

Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion

Roles for miRNAs in endocrine resistance in breast cancer

Contact Info

Product

Resources

About